The Phase III portion of an ongoing Phase II/III trial of Merck and Ridgeback Biotherapeutics’ molnupiravir in mild-to-moderate Covid-19 has enrolled around 1,100 to 1,200 patients of its 1,550-patient target, an investigator said. The trial could complete enrolment in one to two months, assuming worldwide infection continues to spread at its current rate.

A Merck spokesperson said the trial’s enrolment is on track; November is the company’s best guess for when the trial will have enough events for a final analysis. The placebo-controlled Phase III MOVe-OUT study has a primary endpoint of percentage of patients who are hospitalised and/or die over 29 days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is enrolling adults with laboratory-confirmed, mild-to-moderate Covid-19, and at least one risk factor associated with poor disease outcomes. Participants are randomised to either 800mg molnupiravir or placebo twice daily for five days. lists the trial’s estimated primary completion date as 8 November.

Molnupiravir has Phase IIa data showing it can reduce a patient’s viral load. Virus isolation was 1.9% in the 800mg molnupiravir group compared to 16.7% in the placebo group at day three, representing a statistically significant difference, according to a Phase IIa preprint manuscript.

Molnupiravir, an oral ribonucleoside analogue, is also being studied in the Phase III MOVe-AHEAD trial in the postexposure prophylaxis setting. Merck’s collaboration with Miami, Florida-based Ridgeback was announced in May 2020.